ENTRY       D10316                      Drug
NAME        Nivolumab (USAN/INN);
            Nivolumab (genetical recombination) (JAN);
            Opdivo (TN)
PRODUCT     OPDIVO (E.R. Squibb & Sons)
FORMULA     C6362H9862N1712O1995S42
EXACT_MASS  143509.1148
MOL_WEIGHT  143597.3811
SEQUENCE    (Heavy chain)
            QVQLVESGGG VVQPGRSLRL DCKASGITFS NSGMHWVRQA PGKGLEWVAV IWYDGSKRYY
            ADSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCATND DYWGQGTLVT VSSASTKGPS
            VFPLAPCSRS TSESTAALGC LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS
            VVTVPSSSLG TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP
            KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN STYRVVSVLT
            VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE MTKNQVSLTC
            LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV
            MHEALHNHYT QKSLSLSLGK
            (Light chain)
            EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD ASNRATGIPA
            RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ SSNWPRTFGQ GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H127-L214, H140-H196, H219-H'219, H222-H'222, H254-H314, H360-H418, H'22-H'96, H'127-L'214, H'140-H'196, H'254-H'314, H'360-H'418, L-23-L88, L134-L194, L'23-L'88, L'134-L'194)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      Therapeutic category: 4291
            ATC code: L01FF01
            Product: D10316<JP/US>
            Product (mixture): D12334<US>
EFFICACY    Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
  DISEASE   Melanoma [DS:H00038]
            Non-small cell lung cancer [DS:H00014]
            Small cell lung cancer [DS:H00013]
            Malignant pleural mesothelioma [DS:H00015]
            Renal cell carcinoma [DS:H00021]
            Hodgkin lymphoma [DS:H00007]
            Squamous cell carcinoma of the head and neck [DS:H02420]
            Urothelial carcinoma [DS:H00022]
            Colorectal cancer (MSI-H or dMMR) [DS:H00020]
            Hepatocellular carcinoma [DS:H00048]
            Esophageal squamous cell carcinoma [DS:H00017]
            Gastric cancer [DS:H00018]
            Esophageal adenocarcinoma [DS:H00017]
  TYPE      Monoclonal antibody
TARGET      PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  PATHWAY   hsa04514(5133)  Cell adhesion molecules
            hsa04660(5133)  T cell receptor signaling pathway
            hsa05235(5133)  PD-L1 expression and PD-1 checkpoint pathway in cancer
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
                 L01FF01 Nivolumab
                  D10316  Nivolumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Nivolumab
                D10316  Nivolumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D10316  Nivolumab (USAN/INN); Nivolumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D10316  Nivolumab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D10316  Nivolumab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                PDCD1 (PD1, CD279)
                 D10316  Nivolumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10316
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10316
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10316
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10316
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10316
DBLINKS     CAS: 946414-94-4
            PubChem: 163312346
///
